Tag: Nephrology
PharmaSignal — Nephrology
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
March 31, 2026
BioSpace
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in
Biogen swoops on Apellis with $5.6bn offer
March 31, 2026
Pharmaphorum
In today’s second sizeable M A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.